Pharmacovigilance in the era of advanced therapies: safeguarding safety in an increasingly complex healthcare landscape

The changing complexity of safety profiles

Traditional medicines are generally assessed on the basis of relatively predictable pharmacological mechanisms of action and extensive clinical datasets. Advanced therapies are fundamentally different.

Cell and gene therapies can cause long-lasting or even permanent biological changes. Patient populations are also often small, treatment pathways highly individualised and clinical experience limited at the time of launch. Consequently, a significant proportion of the evidence concerning safety is generated after marketing authorisation.

This requires a different way of thinking. The focus is no longer solely on recording adverse events, but on continuously developing a complete and current understanding of a therapy’s benefit-risk profile throughout its lifecycle.

From compliance to strategic risk management

The role of pharmacovigilance has changed significantly in recent years. While the discipline was historically associated primarily with statutory reporting obligations and operational processes, regulators and healthcare organisations now expect it to contribute much more broadly to decision-making.

Modern pharmacovigilance organisations therefore focus on:

• Continuous evaluation of benefit-risk profiles;

• Early identification of emerging safety signals;

• Integration of clinical data and real-world evidence;

• Support for strategic decisions throughout the product lifecycle;

• Transparent communication with patients, healthcare professionals and regulators.

  
  

This shift requires close collaboration between pharmacovigilance, clinical development, medical affairs, regulatory affairs, epidemiology and biostatistics. Safety therefore becomes an integral component of innovation rather than a separate control function.

Data as the foundation of modern drug safety

The volume of available safety information is growing rapidly. In addition to spontaneous reports, organisations have access to data from electronic health records, patient registries, wearables, clinical trials and real-world sources. This creates a far more comprehensive understanding of how medicines perform in routine clinical practice.

The challenge is no longer collecting data, but interpreting them.

Advanced data analytics and artificial intelligence increasingly help organisations identify patterns, prioritise potential safety signals and accelerate complex analyses. At the same time, demand is growing for professionals capable of translating these insights into scientifically substantiated decisions.

Technology increases the speed and scalability of pharmacovigilance, but clinical expertise and critical judgement remain decisive to the quality of final decisions.

Global harmonisation and increasing regulatory expectations

International regulation continues to evolve in response to the pace of scientific innovation. Authorities such as the EMA and FDA are imposing increasingly stringent requirements concerning transparency, data quality, risk evaluation and post-marketing surveillance.

For internationally operating organisations, this means safety processes must be globally consistent while accommodating regional differences in regulation and reporting obligations.

A growing number of organisations are therefore investing in integrated global safety operating models centred on standardisation, governance and data-driven decision-making. These models not only strengthen regulatory compliance, but also improve the speed with which new safety insights can be translated into concrete actions.